Janux Therapeutics is a biotechnology company that develops cancer treatments using its proprietary Tumor Activated T Cell Engager (TRACTr) platform. The company's technology is designed to activate T cells selectively within the tumor microenvironment, leading to targeted cancer cell killing and reduced toxicity. The company was founded in 2017 and is based in Santa Clara, California.